Impact of International Atomic Energy Agency support to the development of nuclear cardiology in low-and-middle-income countries: Case of Latin America and the Caribbean

Autor: Gutierrez-Villamil, C., Peix, A. ^*, Orellana, P., Berrocal, I., Ramirez, R., Estrada-Lobato, E., Paez, D.

Publikováno v: In Journal of Nuclear Cardiology December 2019 26(6):2048-2054

Uso adecuado de las pruebas no invasivas de isquemia para guiar la toma de decisión sobre revascularización tras un infarto agudo de miocardio con elevación del segmento ST en países iberoamericanos: Resultados de la reunión de un panel de expertos de la International Atomic Energy Agency

Autor: Berrocal, I., Peix, A., Mut, F., Shaw, L.J., Karthikeyan, G., Estrada Lobato, E., Paez, D.

Publikováno v: In Revista Española de Medicina Nuclear e Imagen Molecular July-August 2018 37(4):237-243

Guiding principles on the education and practice of theranostics.

Autor: Pascual TNB; Department of Science and Technology, Manila, Philippines., Paez D; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Iagaru A; Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center, Stanford, CA, USA., Gnanasegaran G; Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, UK., Lee ST; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; School of Health and Biomedicine, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, Australia.; Department of Surgery, University of Melbourne, Melbourne, Australia., Sathekge M; Steve Biko Academic Hospital, Pretoria, South Africa.; University of Pretoria, Pretoria, South Africa., Buatti JM; Department of Radiation Oncology, Holden Comprehensive Cancer Center, Carver College of Medicine, University of Iowa, Iowa City, IA, USA., Giammarile F; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Al-Ibraheem A; Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.; School of Medicine, University of Jordan, Amman, Jordan., Pardo MA; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Baum RP; Center for Advanced Radiomolecular Precision Oncology, Curanosticum Wiesbaden, FrankfurtWiesbaden, Germany., De Bari B; Radiation Oncology Department, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland., Ben-Haim S; Department of Biophysics and Nuclear Medicine, Hadassah University Hospital, Jerusalem, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel.; University College London, London, UK., Blay JY; Department of Medicine, Centre Leon Berard, Lyon, France.; University Claude Bernard Lyon, Lyon, France., Brink A; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Estrada-Lobato E; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Fanti S; Nuclear Medicine Division, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Policlinico S.Orsola, Bologna, Italy., Golubic AT; Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia., Hatazawa J; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan., Israel O; B. Rappaport School of Medicine, Israel Institute of Technology-Technion, Haifa, Israel., Kiess A; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Knoll P; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Louw L; Center of Molecular Imaging and Theranostics, Johannesburg, South Africa.; University of the Witwatersrand, Johannesburg, South Africa., Mariani G; Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Mirzaei S; Department of Nuclear Medicine With PET-Centre, Clinic Ottakring, Vienna, Austria., Orellana P; Pontificia Universidad Católica, Santiago, Chile., Prior JO; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland., Urbain JL; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Vichare S; Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria., Vinjamuri S; Nuclear Medicine Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Virgolini I; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., Scott AM; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. andrew.scott@onjcri.org.au.; Olivia Newton-John Cancer Research Institute, Melbourne, Australia. andrew.scott@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia. andrew.scott@onjcri.org.au.; Faculty of Medicine, University of Melbourne, Melbourne, Australia. andrew.scott@onjcri.org.au.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Jul; Vol. 51 (8), pp. 2320-2331. Date of Electronic Publication: 2024 Mar 08.

Production and regulatory issues for theranostics.

Autor: Giammarile F; Division of Human Health, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Paez D; Division of Human Health, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Zimmermann R; Chrysalium Consulting, Lalaye, France; MEDraysintell, Louvain la Neuve, Belgium; Oncidium Foundation, Auderghem, Belgium., Cutler CS; Isotope Research and Production Department, Brookhaven National Laboratory Upton, New York City, NY, USA., Jalilian A; Division of Physical and Chemical Sciences, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Korde A; Division of Physical and Chemical Sciences, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Knoll P; Division of Physical and Chemical Sciences, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Ayati N; Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, Australia., Lewis JS; Department of Radiology and Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, Upton, NY, USA; Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York City, NY, USA., Lapi SE; Departments of Radiology and Chemistry, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA., Delgado Bolton RC; Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja, Logroño, Spain; Servico Cántabro de Salud, Santander, Spain., Kunikowska J; Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland., Estrada Lobato E; Division of Human Health, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Urbain JL; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Holmberg O; Department of Nuclear Science and Applications, and Division of Radiation, Transport and Waste Safety, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Abdel-Wahab M; Division of Human Health, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria., Scott AM; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia. Electronic address: andrew.scott@onjcri.org.au.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Jun; Vol. 25 (6), pp. e260-e269.

Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine.

Autor: Giammarile F; Department of Nuclear Science and Applications, Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria. Electronic address: F.Giammarile@iaea.org., Knoll P; Department of Nuclear Science and Applications, Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria., Paez D; Department of Nuclear Science and Applications, Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria., Estrada Lobato E; Department of Nuclear Science and Applications, Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria., Calapaquí Terán AK; Department of Pathology, University Hospital 'Marqués de Valdecilla', Santander, Spain; Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain., Delgado Bolton RC; Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain; Servicio Cántabro de Salud, Santander, Spain.

Publikováno v: Seminars in nuclear medicine [Semin Nucl Med] 2024 May; Vol. 54 (3), pp. 340-344. Date of Electronic Publication: 2024 Feb 16.